CRWV vs JNJ: Which Is the Better Buy?
Side-by-side comparison of CoreWeave, Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-08-06.
CoreWeave, Inc. · Technology
$89.89
+24.6% upside to fair value
Med Conviction
Grade C+
VS
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
QuantHub Verdict
CRWV has more upside to fair value
(+24.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWV |
JNJ |
| Current Price |
$89.89 |
$253.85 |
| Fair Value Estimate |
$112.00 |
$198.76 |
| Upside to Fair Value |
+24.6%
|
-21.7%
|
| Market Cap |
$49.0B |
$611.1B |
| Forward P/E |
—
|
29.3x
|
| EV / EBITDA |
26.6x
|
19.2x
|
| Price / Sales |
7.9x
|
6.3x
|
| Price / FCF |
—
|
34.3x
|
| Revenue Growth YoY |
+111.6%
|
+9.9%
|
| Gross Margin |
69.4%
|
69.1%
|
| Operating Margin |
-2.6%
|
26.9%
|
| Return on Equity |
-33.5%
|
26.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
-21.6%
|
2.91%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
CoreWeave is the leading neocloud, a GPU-specialized cloud infrastructure provider built to serve the compute-hungry demands of generative AI training and inference. Since its March 2025 IPO, revenue has scaled roughly 112% year over year to $2.08 billion in the first quarter of 2026, backed by a $99.4 billion contracted revenue backlog and marquee agreements with Microsoft, OpenAI, Meta, Anthrop…
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Accumulation Zones
| Metric |
CRWV |
JNJ |
| Zone Low |
$84.00 |
$149.07 |
| Zone High |
$95.00 |
$168.95 |
| In Buy Zone? |
Yes
|
No
|